Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model
Authors:
- Maximilian ThormannMTMaximilian Thormann
- Franziska HeitmannFHFranziska Heitmann
- Vanessa WrobelVWVanessa Wrobel
- Constanze HeinzeCHConstanze Heinze
- Christine MarchCMChristine March
- Peter HassPHPeter Hass
- Robert DammRDRobert Damm
- Alexey SurovASAlexey Surov
- Maciej PechMPMaciej Pech
- Jazan OmariJOJazan Omari
Open Access
- 29 June 2023
- journal article
- research article
- Published by S. Karger AG in Digestive Diseases
- Vol. 41 (6) , 957-966
Abstract
Introduction: Interstitial brachytherapy (iBT) is an effective treatment for hepatocellular carcinoma (HCC). Identification of prognostic factors is pivotal for patient selection and treatment efficacy. This study aimed to assess the impact of low skeletal muscle mass (LSMM) on overall survival (OS) and progression-free survival (PFS) of iBT in patients with HCC. Methods: For this single-center study, we retrospectively identified 77 patients with HCC who underwent iBT between 2011 and 2018. Follow-up visits were recorded until 2020. The psoas muscle area, psoas muscle index, psoas muscle density (MD), and the skeletal muscle gauge were assessed on the L3 level on pre-treatment cross-sectional CT scans. Results: Median OS was 37 months. 42 patients (54.5%) had LSMM. An AFP level of >400 ng/ml (hazard ratio [HR] 5.705, 95% confidence interval [CI]: 2.228–14.606, p = 0.001), BCLC stage (HR 3.230, 95% CI: 0.972–10.735, p = 0.026), and LSMM (HR 3.365, 95% CI: 1.490–7.596, p = 0.002) showed a relevant association with OS. Weighted hazard ratios were used to form a predictive risk stratification model with three groups: patients with low risk (median OS 62 months), intermediate risk (median OS 31 months), and high risk (median OS 9 months). The model showed a good prediction of 1-year mortality, with an AUC of 0.71. Higher MD was associated with better PFS (HR 0.920, 95% CI: 0.881–0.962, p < 0.001). Conclusion: In patients undergoing iBT for HCC, LSMM is associated with worse OS. A risk stratification model based on LSMM, AFP >400 ng/mL, and BCLC stage successfully predicted patient mortality. The model may support and enhance patient selection.Keywords
This publication has 48 references indexed in Scilit:
- Sarcopenia impairs prognosis of patients with liver cirrhosisNutrition, 2015
- Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B‐cell lymphoma treated with immunochemotherapyEuropean Journal of Haematology, 2014
- Clinical relevance of sarcopenia in patients with cirrhosisWorld Journal of Gastroenterology, 2014
- Effect of physical exercise on muscle mass and strength in cancer patients during treatment—A systematic reviewCritical Reviews in Oncology/Hematology, 2013
- Consilience in sarcopenia of cirrhosisJournal of Cachexia, Sarcopenia and Muscle, 2012
- Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (>7 cm) tumoursEuropean Radiology, 2011
- The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexiaJournal of Cachexia, Sarcopenia and Muscle, 2011
- Chemoembolization for Hepatocellular Carcinoma: Multivariate Analysis of Predicting Factors for Tumor Response and Survival in a 362-Patient CohortJournal of Vascular and Interventional Radiology, 2011
- Local Response and Impact on Survival After Local Ablation of Liver Metastases From Colorectal Carcinoma by Computed Tomography–Guided High-Dose-Rate BrachytherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Computed Tomography–Guided High-Dose-Rate Brachytherapy in Hepatocellular Carcinoma: Safety, Efficacy, and Effect on SurvivalInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010